By clicking on the “I agree to the above conditions” button you consent to Parexel International processing your personal information in accordance with this Data Protection Consent for recipient of the Study Alert Mailing List.
Data Protection Consent for Recipients of Study Alert Mailing List
You understand that the Clinical Pharmacology Research Unit of Parexel International Ltd. Level 7, Northwick Park Hospital, Watford Road, Harrow, HA1 3UJ (in the following “Parexel International”) is the controller of the personal data I provide herewith. Parexel International shall process your personal data for the purpose to add you to the London clinical unit Study Alert Mailing List.
Your personal data will be retained as long as necessary for the purposes it has been collected for, but not longer than 3 years without you being contacted again. Parexel International reserves the right to disclose all information collected to the extent required by law.
Parexel International USA, the ultimate parent company of Parexel International Ltd., implemented a communication system operated by the third party vendor Salesforce located in the USA which will allow you to receive notifications about clinical trials and activities at our London clinical unit via e-mail. Note: Both the vendor, Salesforce, as well as Parexel International USA, operate under the EU-US Privacy Shield Framework regarding the collection, use, and retention of personal data transferred from EEA member countries to the U.S. Please visit the following web pages to learn more about Salesforce's and Parexel's self-certification to the EU-US Privacy Shield Framework:
•Parexel ‘s EU-US Privacy Shield Notice https://www.parexel.com/company/privacy-shield-notice
•Salesforce's EU Data Transfer Mechanisms FAQ https://www.salesforce.com/company/privacy/.
In the future, Parexel may opt to work with other third party vendors located in the USA or in other countries, to implement the communication system. Parexel will ensure that in such case the transfer of your personal data to such vendor will be covered by the EU-US Privacy Shield Framework or another transfer mechanism approved by the EU. Parexel will notify you in case of use of any other third party vendor.
Whilst completing the registration questionnaire, you understand that if you quit at any time prior to submitting the form, no record of the information you have provided up to that point will be saved.
If you no longer wish to receive e-mails from the London clinical unit Study Alert Mailing List, you can opt-out at any time by sending an e-mail to email@example.com. You should state your name and email address on such communications and a member of Parexel International's team will ‘deactivate’ your Study Alert Mailing List account.
You understand that you can request access to and/or correction of your personal data by contacting Parexel International in writing at the address mentioned above.
Thank you for your interest.
You will now be notified of future clinical trials at our office. Please check your e-mail for a confirmation message. Click here to return to our list of available studies.